Heat Biologics, Inc. (NASDAQ:HTBX)’s share price was up 0.4% during trading on Friday . The company traded as high as $0.57 and last traded at $0.56, with a volume of 118,176 shares. The stock had previously closed at $0.56.

A number of equities analysts recently commented on HTBX shares. Zacks Investment Research cut shares of Heat Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. Noble Financial reaffirmed a “buy” rating on shares of Heat Biologics in a research note on Sunday, May 14th. Finally, ValuEngine cut shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th.

The company’s market capitalization is $19.68 million. The stock’s 50 day moving average is $0.51 and its 200-day moving average is $0.70.

Several large investors have recently made changes to their positions in HTBX. KCG Holdings Inc. boosted its stake in shares of Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 45,831 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Heat Biologics by 11.9% in the second quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock worth $403,000 after buying an additional 70,290 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in shares of Heat Biologics during the first quarter worth $2,176,000. Institutional investors and hedge funds own 8.74% of the company’s stock.

WARNING: “Heat Biologics, Inc. (HTBX) Trading Up -0.4%” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/02/heat-biologics-inc-htbx-trading-up-0-4-2.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.